IMMUNOHISTOCHEMISTRY, CHROMOGRANIN A

The IHC – Chromogranin A test is an immunohistochemistry-based diagnostic assay used to detect Chromogranin A protein expression in tissue samples. Chromogranin A is a protein found within the secretory granules of neuroendocrine cells, making it one of the most important and widely used markers for identifying neuroendocrine differentiation in tumors.

This test is commonly used in pathology to diagnose and classify neuroendocrine tumors (NETs), including carcinoid tumors and neuroendocrine carcinomas. Chromogranin A staining helps pathologists determine whether a tumor originates from neuroendocrine cells and assists in distinguishing these tumors from other cancer types.

Benefits of the Test

• Helps diagnose neuroendocrine tumors
• Assists in identifying neuroendocrine cell differentiation
• Supports classification of endocrine-related cancers
• Improves tumor origin identification
• Helps guide oncology treatment planning

Why Doctors Recommend This Test

Doctors recommend the IHC Chromogranin A test when there is suspicion of neuroendocrine tumors or endocrine-related malignancies. It is commonly used in:

• Diagnosis of neuroendocrine tumors (NETs)
• Evaluation of carcinoid tumors
• Assessment of pancreatic neuroendocrine tumors
• Investigation of gastrointestinal neuroendocrine neoplasms
• Oncology biopsy interpretation and tumor classification

Chromogranin A is often used together with markers such as Synaptophysin, CD56, NSE, Ki-67, and INSM1 to provide comprehensive neuroendocrine tumor profiling.

Preparation Before Test

No special preparation is required from the patient. Important considerations include:

• The test is performed on a biopsy or surgical tissue sample
• No fasting or medication restrictions are necessary
• Clinical history, imaging findings, and pathology reports may assist interpretation

Normal Reporting Time

The typical turnaround time is 3 to 5 working days, depending on specimen processing and laboratory workflow.

Who Should Take This Test

• Patients with suspected neuroendocrine tumors
• Individuals with pancreatic endocrine tumors
• Cases of carcinoid tumor evaluation
• Patients undergoing gastrointestinal tumor assessment
• Oncology patients requiring neuroendocrine tumor classification

The IHC Chromogranin A test is an essential diagnostic tool in modern pathology and oncology. By detecting neuroendocrine cell markers in tissue samples, it helps clinicians accurately diagnose neuroendocrine tumors and develop appropriate treatment strategies.

Clinical Significance

Chromogranin A is considered one of the most reliable markers for neuroendocrine differentiation and is frequently used to confirm the diagnosis of:

• Gastrointestinal neuroendocrine tumors
• Pancreatic neuroendocrine tumors
• Carcinoid tumors
• Neuroendocrine carcinomas
• Certain endocrine gland tumors